Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Alcidion Group Limited ( (AU:ALC) ).
Alcidion Group Limited reported a transformative financial year in FY25, achieving a record underlying EBITDA of $5.1 million and a 10% increase in revenue to $40.8 million. The company secured significant new contracts, including a major Electronic Patient Record deployment with North Cumbria NHS Trust, validating its dual market position. With a strong cash balance and no debt, Alcidion is poised for further growth in FY26, leveraging its Miya platform to expand into new markets and enhance patient flow solutions.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
More about Alcidion Group Limited
Alcidion Group Limited operates in the healthcare technology industry, providing enterprise health technology solutions. Their primary product, Miya Precision, addresses significant healthcare challenges such as reducing emergency presentations, streamlining patient flow, and accelerating patient discharge. The company focuses on markets in the UK and Australia, offering modular and comprehensive platform solutions.
Average Trading Volume: 1,304,886
Technical Sentiment Signal: Buy
Current Market Cap: A$134.3M
For a thorough assessment of ALC stock, go to TipRanks’ Stock Analysis page.